Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gut
Asıl Yazarlar: Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2017
Konular:
Hepatology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595101/
https://ncbi.nlm.nih.gov/pubmed/27418632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-311609
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller